

Achilles Therapeutics Plc (in Members Voluntary Liquidation)

Notice of Second and Final Distribution to the holders of Ordinary Shares and American Depositary Shares (“ADS”)

Following the appointment of the Joint Liquidators on 20 March 2025, a first interim liquidation distribution to the holders of Ordinary Shares in Achilles Therapeutics plc (in Liquidation) was declared on 28 May 2025 at the rate of £1.10 per Ordinary Share.

A second and final cash distribution was declared on 11 September 2026. This cash distribution was made at a rate of **£0.2260 per Ordinary Share** and paid in Pounds Sterling (“GBP”). All Ordinary shareholders have been contacted directly by the Joint Liquidators.

There are currently 42,559,102 Ordinary Shares in issue with the majority being held by the Bank of New York Mellon (the “Depositary”) which facilitates an American Depositary Share (“ADS”) program for Achilles Therapeutics plc which is US Dollar (“USD”) denominated. As per the [Circular](#), the Depositary has set and announced a separate record date for the payment of its Second and Final distribution to the registered holders of ADSs (who are not Sanctions Restricted Persons), in accordance with the Depositary Agreement.

On 22 September 2026, the Depositary provided confirmation of the second and final cash distribution to ADS holders, a copy of which can be located [here](#) (the “Notice”). There are currently 35,017,180 outstanding ADSs and the ADS distribution rate, after the conversion from GBP to USD and Depositary costs, is **\$0.275977 per ADS**.

Per the Notice, the Depositary has converted amounts received from the Joint Liquidators in GBP into USD using the FX Methodology available via its [Website](#). The Depositary has also deducted a distribution fee of \$0.025 per ADS in accordance with the Depositary Agreement and the Circular.

The ADS cash distribution will be payable from 29 September 2026. ADS holders will have to be registered holders, or beneficial owners, of ADSs through a brokerage firm, bank or nominee that is a registered holder of ADSs, as of the record date set by the Depositary to be eligible to receive distributions.

Queries regarding the ADS distributions should be directed to your broker or the platform provider through which you hold your ADSs. Alternatively, queries relating to receipt of funds, from the Depositary, can be directed to the phone numbers listed on the Notice.

Cumulative outcome and next steps

A combined value of £1.3260 has been returned to Ordinary shareholders, per Ordinary share and \$1.7346 before costs has been returned to ADS holders.

Pre-liquidation guidance on total returns to all shareholders, as per the Circular and before costs and fees, was a range of approximately £1.20 to £1.32 per Ordinary share and \$1.50 to \$1.66 per ADS.

Following the final distribution the Joint Liquidators will be taking steps to bring the liquidations of the company and its subsidiaries to a conclusion.

For the avoidance of any doubt, please note there will be no further distributions made by the Joint Liquidators.